1. Pink Sheet

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition

 
• By Eileen Francis

GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.

GlaxoSmithKline PLC expects its Flonase SensimistAllergy Relief (fluticasone furoate/27.5mcg spray) to build upon the success of the original Flonase OTC line and help counter recent private label competitive activity in the intranasal corticosteroid category.

“We’re very optimistic that we can follow the huge success of Flonase,” said CEO Andrew Witty on Feb

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance